|22nd December 2020||Management Inc. Opaleye||15,900||Open or private purchase||$5.19||$82,597.32|
|22nd December 2020||Management Inc. Opaleye||657||Open or private purchase||$5.19||$3,412.98|
|22nd December 2020||Management Inc. Opaleye||496,277||Open or private purchase||$8.06||$3,999,992.62|
|21st December 2020||Management Inc. Opaleye||51,400||Open or private purchase||$5.24||$269,305.16|
|21st December 2020||Management Inc. Opaleye||2,059||Open or private purchase||$5.24||$10,787.92|
|18th December 2020||Management Inc. Opaleye||1,400||Open or private purchase||$5.31||$7,437.64|
|18th December 2020||Management Inc. Opaleye||35,000||Open or private purchase||$5.31||$185,941.00|
|7th December 2020||Richard L Md Lindstrom||32,127||Grant/award etc.||$0.00|
|4th December 2020||Charles M Warden||745,597||Other acquisition or disposition||$0.00|
|4th December 2020||Charles M Warden||3,619||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Ocular Therapeutix, Inc. is a biopharmaceutical company. It engages in the development and commercialization of therapies for diseases and conditions of the eye. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi in 2006.